D-0095-2024 Class II Ongoing

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0095-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 20, 2023 and is designated Class II. Reason for recall: Failed Dissolution Specifications The recall status is ongoing. Affected quantity: 5,856 bottles.

Recall details

Product Type
Drugs
Report Date
Nov 15, 2023
Initiation Date
Oct 20, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
5,856 bottles

Product description

Deferasirox Tablets for Oral Suspension, 500mg, 30-count bottle, Rx only, Manufactured for: Glenmark Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India, NDC 68462-496-30

Reason for recall

Failed Dissolution Specifications

Distribution pattern

USA nationwide

Code information

Lot #: 17220063, Exp 12/2023; 17220396, 17220397, Exp 01/2024; 17220965, Exp 04/2024; 17221187, 17221523, Exp 07/2024; 17221793, 17221794, 17221801, Exp 08/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0095-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0095-2024. Report a data issue: hello@regdatalab.com.